Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Good And Bad News For Genzyme MS Drugs At NICE: Aubagio In; Lemtrada Out For Now

This article was originally published in The Pink Sheet Daily

Executive Summary

Genzyme had a mixed few days with its MS drugs at NICE, with Aubagio finally succeeding but Lemtrada struggling on the back of a tough benefit/risk profile.

You may also be interested in...

NICE’s Tecfidera Restrictions In MS Leave It Fighting For U.K. Market Share

Biogen Idec get nod after providing more data, but restrictions imposed mean Tecfidera is unlikely to leap ahead of a packed field.

NICE's Unrestricted MS Indication For Lemtrada Could Boost It Ahead Of Rivals

Though not totally convinced about long-term effectiveness and patient adherence, NICE's decision not to restrict Lemtrada's indication could place it ahead of Gilenya and Tysabri for relapsing-remitting multiple sclerosis.

Biogen’s Tecfidera Hit At NICE By Data Shortage, Functional Unblinding

NICE has demanded more data and analyses for Biogen Idec’s MS champion, Tecfidera, before it clears a drug expected to be a worthy opponent for Novartis’ Gilenya.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts